Laboratorios Rovi (BME:ROVI) Stock Questioned As One Off Gain Lifts Reported Margins
Laboratorios Farmaceuticos Rovi (BME:ROVI) has released its Q2 2026 results with revenue of €191.7 million and net income of €75.0 million, set against trailing 12 month revenue of €773.1 million, net income of €185.2 million, and Basic EPS of €3.61 that reflects a 40% year over year earnings increase. Over recent quarters the company has seen revenue move from €159.7 million in Q2 2025 to €210.5 million in Q3 2025, €218.4 million in Q4 2025, €152.5 million in Q1 2026 and now €191.7 million. Over the same trailing 12 month period, net profit margin has shifted from 17.7% to 24%, partly shaped by a €62.4 million one off gain. For investors, the latest print points to earnings power that looks healthy on the surface, with margins that appear solid but call for closer scrutiny beneath the headline figures.
See our full analysis for Laboratorios Farmaceuticos Rovi.With the numbers on the table, the next step is to line up these results against the key narratives around Laboratorios Farmaceuticos Rovi to see which stories the data supports and which ones start to look less convincing.
See what the community is saying about Laboratorios Farmaceuticos Rovi
Margins Lifted By €62.4m One Off Gain
- Trailing net profit margin sits at 24% versus 17.7% a year earlier, with the last 12 months including a €62.4 million one off gain that inflates reported profitability.
- Bears focus on how much of Laboratorios Farmaceuticos Rovi’s recent strength rests on temporary supports, and the margin picture gives them numbers to work with:
- Trailing 12 month net income of €185.2 million and Basic EPS of €3.61 come alongside a five year trend of EPS slipping about 1% per year, which critics view as a weaker long run backdrop than the latest margin figure suggests.
- With analysts expecting EPS to grow about 11.2% per year from here, bears question how much of that path assumes margins close to the recent 24% level rather than a lower figure that strips out the €62.4 million boost.
Revenue Trend Versus Product Dependence
- On a trailing basis, revenue is €773.1 million with reported growth of 8.9% per year compared with a 6.8% forecast for the wider Spanish market, while quarterly sales have moved within a band of about €152.5 million to €218.4 million over the last five reported quarters.
- Consensus narrative highlights strong growth engines but also concentration risk, and the recent numbers give both sides of that story:
- Supporters point to reported revenue growth of 8.9% per year and a higher trailing margin as evidence that products like Okedi and heparin based treatments, along with contract manufacturing, are pulling their weight financially.
- Cautious investors look back at periods where total revenue slipped, along with guidance previously calling for mid single digit declines, and link that to the risk that reliance on a narrow group of specialty products and CDMO contracts could lead to uneven revenue contributions over time.
ROVI Valuation Versus Earnings Quality
- Laboratorios Farmaceuticos Rovi trades on a P/E of 16.2x against peer and industry averages of 36.9x and 21.9x, with the share price at €58.8 compared with an analyst price target of €74.36 and a DCF fair value of €109.13.
- Bulls argue that this valuation gap reflects opportunity rather than a warning sign, and today’s figures give them some support but also clear caveats:
- The trailing 12 month earnings rise of 40% and margin at 24% help explain why a P/E of 16.2x screens lower than peers, which bullish investors see as a potential mispricing when set against the €74.36 target and DCF fair value of €109.13.
- At the same time, the €62.4 million one off gain inside those earnings means anyone leaning on the valuation case alone needs to think about what the multiple would look like if earnings were adjusted to exclude that item.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Laboratorios Farmaceuticos Rovi on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Does the mix of risks and rewards around Laboratorios Farmaceuticos Rovi feel balanced enough for you? If you want to move quickly and test that view against a fuller breakdown of the key concerns and potential upsides, take a closer look at the 5 key rewards and 2 important warning signs.
See What Else Is Out There
For Laboratorios Farmaceuticos Rovi, reliance on a one off €62.4 million gain and concentration in a narrow set of products raises questions about earnings quality and resilience.
If that mix of one off boosts and product concentration makes you want steadier stories, check out 293 resilient stocks with low risk scores to focus on companies with more resilient profiles right now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com